NCT01454583View on ClinicalTrials.gov

Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany

CompletedOBSERVATIONAL
Enrollment

15,337

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

July 31, 2012

Conditions
Arterial Hypertension
Interventions
DRUG

Aliskiren

Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.

DRUG

ACE-I/ARB

DRUG

No RAS-inhibition

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Stiftung Institut fuer Herzinfarktforschung

OTHER